These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23761390)

  • 21. Variation within the serotonin (5-HT) 5-HT₂C receptor system aligns with vulnerability to cocaine cue reactivity.
    Anastasio NC; Liu S; Maili L; Swinford SE; Lane SD; Fox RG; Hamon SC; Nielsen DA; Cunningham KA; Moeller FG
    Transl Psychiatry; 2014 Mar; 4(3):e369. PubMed ID: 24618688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI.
    Wingen M; Kuypers KP; Ramaekers JG
    J Psychopharmacol; 2007 Jul; 21(5):477-85. PubMed ID: 17092965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanisms of action of antidepressants: new data from Escitalopram].
    Fabre V; Hamon M
    Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: impact of gender and cue type.
    Fox HC; Sofuoglu M; Morgan PT; Tuit KL; Sinha R
    Psychoneuroendocrinology; 2013 Sep; 38(9):1532-44. PubMed ID: 23374328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Acetylcysteine reduces cocaine-cue attentional bias and differentially alters cocaine self-administration based on dosing order.
    Levi Bolin B; Alcorn JL; Lile JA; Rush CR; Rayapati AO; Hays LR; Stoops WW
    Drug Alcohol Depend; 2017 Sep; 178():452-460. PubMed ID: 28711811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-related stimuli impair inhibitory control in cocaine abusers.
    Pike E; Stoops WW; Fillmore MT; Rush CR
    Drug Alcohol Depend; 2013 Dec; 133(2):768-71. PubMed ID: 24004904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single dose of citalopram increases fear recognition in healthy subjects.
    Browning M; Reid C; Cowen PJ; Goodwin GM; Harmer CJ
    J Psychopharmacol; 2007 Sep; 21(7):684-90. PubMed ID: 17259206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.
    Langley C; Armand S; Luo Q; Savulich G; Segerberg T; Søndergaard A; Pedersen EB; Svart N; Overgaard-Hansen O; Johansen A; Borgsted C; Cardinal RN; Robbins TW; Stenbæk DS; Knudsen GM; Sahakian BJ
    Neuropsychopharmacology; 2023 Mar; 48(4):664-670. PubMed ID: 36683090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a selective serotonin reuptake inhibitor escitalopram on the cutaneous silent period: a randomized controlled study in healthy volunteers.
    Pujia F; Serrao M; Brienza M; Vestrini E; Valente GO; Coppola G; Pierelli F
    Neurosci Lett; 2014 Apr; 566():17-20. PubMed ID: 24589881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixation time is a sensitive measure of cocaine cue attentional bias.
    Marks KR; Roberts W; Stoops WW; Pike E; Fillmore MT; Rush CR
    Addiction; 2014 Sep; 109(9):1501-8. PubMed ID: 24894879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
    Nadeem HS; Attenburrow MJ; Cowen PJ
    Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SSRI effects on pyschomotor performance: assessment of citalopram and escitalopram on normal subjects.
    Paul MA; Gray GW; Love RJ; Lange M
    Aviat Space Environ Med; 2007 Jul; 78(7):693-7. PubMed ID: 17679567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval.
    Reed MB; Vanicek T; Seiger R; Klöbl M; Spurny B; Handschuh P; Ritter V; Unterholzner J; Godbersen GM; Gryglewski G; Kraus C; Winkler D; Hahn A; Lanzenberger R
    Neuroimage; 2021 Aug; 236():118039. PubMed ID: 33852940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence.
    Ersche KD; Bullmore ET; Craig KJ; Shabbir SS; Abbott S; Müller U; Ooi C; Suckling J; Barnes A; Sahakian BJ; Merlo-Pich EV; Robbins TW
    Arch Gen Psychiatry; 2010 Jun; 67(6):632-44. PubMed ID: 20530013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial.
    Moeller FG; Schmitz JM; Steinberg JL; Green CM; Reist C; Lai LY; Swann AC; Grabowski J
    Am J Drug Alcohol Abuse; 2007; 33(3):367-78. PubMed ID: 17613964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attentional bias to cannabis cues in cannabis users but not cocaine users.
    Alcorn JL; Marks KR; Stoops WW; Rush CR; Lile JA
    Addict Behav; 2019 Jan; 88():129-136. PubMed ID: 30176501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Stroop: Mechanisms of response to computerized cognitive behavioral therapy for cocaine dependence in a randomized clinical trial.
    DeVito EE; Kiluk BD; Nich C; Mouratidis M; Carroll KM
    Drug Alcohol Depend; 2018 Feb; 183():162-168. PubMed ID: 29258028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.
    Zoons E; Tijssen MAJ; Dreissen YEM; Smit M; Booij J
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32521736
    [No Abstract]   [Full Text] [Related]  

  • 40. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
    Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
    Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.